Osteoporosis Treatment: When to Discontinue and When to Re-start

被引：15

作者：

Adami, Silvano ^{[1
]}

Idolazzi, Luca ^{[1
]}

Fracassi, Elena ^{[1
]}

Gatti, Davide ^{[1
]}

Rossini, Maurizio ^{[1
]}

机构：

[1] Univ Verona, Rheumatol Unit, I-37126 Verona, Italy

来源：

BONE RESEARCH | 2013年 / 1卷

关键词：

osteoporosis treatment; bisphosphonates; duration of osteoporosis treatment; BONE-MINERAL DENSITY; FRACTURE RISK REDUCTION; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; ZOLEDRONIC ACID; RANDOMIZED-TRIAL; ALENDRONATE; RISEDRONATE; TERIPARATIDE; BISPHOSPHONATES;

D O I：

10.4248/BR201304003

中图分类号：

Q813 [细胞工程];

学科分类号：

100113 [医学细胞生物学];

摘要：

A number of effective therapies for the treatment of osteoporosis have become available in recent years. However, uncertainty exists regarding their long-term use and effectiveness. Bisphosphonate treatment, unlike hormone replacement, denosumab or teriparatide, is associated with benefits extended even after treatment discontinuation. The extended benefits are most apparent for alendronate (ALN) and zoledronate (ZOL). A drug holiday might be considered in patients at low-moderate risk and who have been fully compliant with treatment, and who have had a response to treatment. In patients at low-moderate risk of fractures the decision to consider a drug holiday should be balanced also with the safety profile of each treatment.

引用

页码：323 / 335

页数：13

共 44 条

[1]

Adverse Effects of Bisphosphonates [J].

Abrahamsen, Bo .

CALCIFIED TISSUE INTERNATIONAL, 2010, 86 (06) :421-435

[2]

Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis [J].

Adami, S. ;

Martin, J. San ;

Munoz-Torres, M. ;

Econs, M. J. ;

Xie, L. ;

Dalsky, G. P. ;

McClung, M. ;

Felsenberg, D. ;

Brown, J. P. ;

Brandi, M. L. ;

Sipos, A. .

OSTEOPOROSIS INTERNATIONAL, 2008, 19 (01) :87-94

[3]

Guidelines for the diagnosis, prevention and treatment of osteoporosis [J].

Adami, S. ;

Bertoldo, F. ;

Brandi, M. L. ;

Cepollaro, C. ;

Filipponi, P. ;

Fiore, E. ;

Frediani, B. ;

Giannini, S. ;

Gonnelli, S. ;

Isaia, G. C. ;

Luisetto, G. ;

Mannarino, E. ;

Marcocci, C. ;

Masi, L. ;

Mereu, C. ;

Migliaccio, S. ;

Minisola, S. ;

Nuti, R. ;

Rini, G. ;

Rossini, M. ;

Varenna, M. ;

Ventura, L. ;

Bianchi, G. .

REUMATISMO, 2009, 61 (04) :260-284

[4]

Adverse effects of bisphosphonates - A comparative review [J].

Adami, S ;

Zamberlan, N .

DRUG SAFETY, 1996, 14 (03) :158-170

[5]

The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years [J].

Andrews, Elizabeth B. ;

Gilsenan, Alicia W. ;

Midkiff, Kirk ;

Sherrill, Beth ;

Wu, Yun ;

Mann, Beth H. ;

Masica, Daniel .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (12) :2429-2437

[6]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[7]

Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? [J].

Black, Dennis M. ;

Bauer, Douglas C. ;

Schwartz, Ann V. ;

Cummings, Steven R. ;

Rosen, Clifford J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) :2051-2053

[8]

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].

Black, Dennis M. ;

Reid, Ian R. ;

Boonen, Steven ;

Bucci-Rechtweg, Christina ;

Cauley, Jane A. ;

Cosman, Felicia ;

Cummings, Steven R. ;

Hue, Trisha F. ;

Lippuner, Kurt ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Martinez, Ruvie Lou Maria ;

Tan, Monique ;

Ruzycky, Mary Ellen ;

Su, Guoqin ;

Eastell, Richard .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :243-254

[9]

Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[10]

Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].

Black, DM ;

Thompson, DE ;

Bauer, DC ;

Ensrud, K ;

Musliner, T ;

Hochberg, MC ;

Nevitt, MC ;

Suryawanshi, S ;

Cummings, SR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124

← 1 2 3 4 5 →